Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • High Postcancer Medical Bills
  • Federal Workers’ Health Data
  • Cyberattacks on Hospitals
  • ‘Cheap’ Insurance

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Mar 11 2021

Full Issue

Mexico Set To Legalize Personal, Medical Marijuana Use

Mexico nears legalizing personal cannabis use, with strict limits, as the lower house of Congress approved a decriminalization bill. Around the globe, the EU approves Johnson & Johnson's coronavirus vaccine, but Denmark pauses AstraZeneca vaccines over clotting worries.

The New York Times: Mexico Set to Legalize Marijuana, Becoming World’s Largest Market

Lawmakers in Mexico approved a bill Wednesday night to legalize recreational marijuana, a milestone for the country, which is in the throes of a drug war and could become the world’s largest cannabis market, leaving the United States between two pot-selling neighbors. The 316-to-129 vote in Mexico’s lower house, the Chamber of Deputies, came more than two years after the Mexican Supreme Court ruled that the country’s ban on recreational marijuana was unconstitutional and more than three years after the country legalized medicinal cannabis. (Lopez, 3/10)

Reuters: Mexico's Congress Approves Landmark Cannabis Bill

Mexico’s lower house of Congress on Wednesday approved a bill that would decriminalize cannabis for recreational, medical and scientific uses, bringing it a step closer to creating one of the world’s largest markets for the plant. Backed by the administration of President Andres Manuel Lopez Obrador, the bill marks a major shift in a country bedeviled for years by violence between feuding drug cartels. Lawmakers approved the bill in general with 316 votes in favor and 127 against. Now, the Senate needs to review and approve the bill. (Oré, 3/10)

AP: Mexican President Says Poppy Growing Being Studied

Mexican President Andrés Manuel López Obrador said Monday the government is studying what to do about growers of opium poppies who have been hit by competition from synthetic opioids, suggesting that some sort of legalization scheme might be possible. Asked about legalizing marijuana production — a bill for which is now before Congress — López Obrador said the question also involves opium poppies grown illegally in some parts of Mexico to make heroin. “As far as commercializing marijuana and opium poppies, the decision has been made to undertake a thorough study of these crops,” López Obrador said. (3/8)

In other global developments —

Politico: EU Regulator Recommends J&J Coronavirus Vaccine For Use 

The European Medicines Agency said Thursday that Johnson & Johnson’s single-shot coronavirus vaccine is safe and effective to use in everyone over the age of 18. That paves the way for the European Commission to grant the American vaccine a conditional marketing authorization later Thursday. It will be the fourth vaccine approved in the EU after BioNTech/Pfizer, Moderna and Oxford/AstraZeneca. (Deutsch, 3/11)

CNBC: Denmark Suspends Use Of AstraZeneca Vaccine Over Reports Of Blood Clots

Denmark has announced that it will temporarily suspend the use of the coronavirus vaccine developed by AstraZeneca and the University of Oxford. The Danish Health Authority said Thursday that it would temporarily stop using the shot in its vaccination program as a precaution “after reports of severe cases of blood clots in people who have been vaccinated with the COVID-19 vaccine from AstraZeneca.” (Ellyatt, 3/11)

Roll Call: Other Deadly Diseases Spreading Globally Because Of COVID-19 Disruption

While the world is understandably focused on countering the coronavirus pandemic, a secondary global public health crisis has been brewing: a drop-off in vaccination rates against a range of other dangerous infectious diseases. A year ago, when much of the world’s population began to socially distance to reduce the spread of COVID-19, an unfortunate consequence of that countermeasure was a steep decline in the number of children receiving their routine vaccinations for diseases such as measles, rubella and polio. (Oswald, 3/10)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 22
  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
  • Thursday, April 16
  • Wednesday, April 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF